Your session is about to expire
← Back to Search
Kinase Inhibitor
Trastuzumab Deruxtecan + Azenosertib for Stomach Cancer
Phase 1
Recruiting
Led By Funda Meric-Bernstam
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
T-DXd (DS-8201a)-naIve disease
CCNE1 amplification,
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group
Summary
"This trial is testing a new combination treatment of azenosertib and trastuzumab deruxtecan for patients with HER2-positive cancers. Azenosertib targets a protein
Who is the study for?
This trial is for adults with HER2-positive and cyclin E amplified gastric or gastroesophageal junction cancer, as well as other HER2-positive solid tumors that are advanced, metastatic, or unresectable. Participants must have recovered from previous therapy side effects and have an adequate performance status.
What is being tested?
The trial tests the safety and optimal dose of azenosertib combined with trastuzumab deruxtecan in treating certain cancers. Azenosertib inhibits Wee1 protein to enhance tumor cell vulnerability, while trastuzumab deruxtecan targets and kills HER2 positive cancer cells.
What are the potential side effects?
Both azenosertib and trastuzumab deruxtecan can cause fatigue among other side effects. The combination treatment aims to be safe but may also lead to additional risks which will be monitored throughout the study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have never been treated with T-DXd (DS-8201a).
Select...
My cancer has CCNE1 amplification.
Select...
I have never been treated with T-DXd (DS-8201a).
Select...
My cancer shows HER2 presence through specific tests.
Select...
My cancer shows some level of HER2 protein or has more HER2 genes.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of adverse events (AEs)
Incidence of dose limiting toxicities (DLTs)
Maximum tolerated dose
Secondary study objectives
Duration of response
Objective response rate (ORR)
Pharmacodynamic effects in the tumor
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Dose expansion, Cohort 2 (T-DXd, azenosertib)Experimental Treatment7 Interventions
Patients receive treatment as in the dose escalation arm. Patients also undergo ECHO or MUGA and collection of blood samples at screening and on study and undergo CT or MRI throughout the trial. Patients also undergo biopsy at screening and on study.
Group II: Dose expansion, Cohort 1 (T-DXd, azenosertib)Experimental Treatment8 Interventions
Patients receive T-DXd IV over 30-90 minutes on day 1 of each cycle and azenosertib PO QD on days 8-12 and 15-19 of cycle 1 and days 1-5, 8-12, and 15-19 in subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA and collection of blood samples at screening and on study and undergo CT or MRI throughout the trial. Patients also undergo biopsy at screening and on study.
Group III: Dose escalation (T-DXd, azenosertib)Experimental Treatment7 Interventions
Patients receive T-DXd IV over 30-90 minutes on day 1 of each cycle and azenosertib PO QD on days 1-5, 8-12, and 15-19 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA and collection of blood samples at screening and on study and undergo CT or MRI throughout the trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trastuzumab Deruxtecan
2021
Completed Phase 2
~100
Biopsy
2014
Completed Phase 4
~1090
Computed Tomography
2017
Completed Phase 2
~2740
Multigated Acquisition Scan
2015
Completed Phase 3
~270
Biospecimen Collection
2004
Completed Phase 3
~2020
Echocardiography
2013
Completed Phase 4
~11580
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
13,920 Previous Clinical Trials
41,017,068 Total Patients Enrolled
Funda Meric-BernstamPrincipal InvestigatorUniversity of Texas MD Anderson Cancer Center LAO
7 Previous Clinical Trials
12,818 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger